Literature DB >> 22302208

Combination therapy with an angiotensin II receptor blocker and an HMG-CoA reductase inhibitor in experimental subtotal nephrectomy.

Alejandro Álvarez-Prats1, Octavio Hernández-Perera, Pilar Díaz-Herrera, Álvaro C Ucero, Aránzazu Anabitarte-Prieto, Antonio Losada-Cabrera, Alberto Ortiz, José C Rodríguez-Pérez.   

Abstract

BACKGROUND: Angiotensin receptor 1 blockers (ARB) are standard nephroprotective drugs in chronic kidney disease. There is less evidence for a nephroprotective effect of HMG-CoA reductase inhibitors (statins) and much less is known about potential benefits of combination therapy. We evaluated the therapeutic potential of a statin alone or in combination with an ARB in experimental chronic kidney disease.
METHODS: Subtotally nephrectomized (5/6 Nx) rats were treated early with vehicle, losartan, cerivastatin or losartan/cerivastatin. Expression of messenger RNA (mRNA) was assessed by real-time reverse transcription-polymerase chain reaction. Tissue proteins were localized by immunohistochemistry. Nuclear factor-κB (NF-κB) activation was measured in whole kidneys.
RESULTS: In contrast to the sham group, at 6 weeks, vehicle-treated 5/6 Nx rats displayed renal lesions, albuminuria and increased blood pressure, serum creatinine and total kidney NF-κB p65 DNA-binding activity and preproendothelin-1, fibronectin and type I and III collagen mRNA. NF-κB activation correlated with albuminuria and histological renal injury. Losartan or combination therapy preserved renal function, abrogated albuminuria and improved glomerular and interstitial histology. Cerivastatin alone preserved renal function and improved interstitial injury but did not influence albuminuria, glomerular histology or NF-κB activation. Losartan/cerivastatin normalized kidney NF-κB activation and extracellular matrix mRNA expression pattern. The effect of losartan alone on these parameters was less intense. All treatments decreased preproendothelin-1 mRNA and preserved interstitial capillaries.
CONCLUSIONS: In a chronic kidney disease model, early treatment with either an ARB or a statin preserved renal function although the mechanisms differed. Combination therapy with an ARB and a statin did not confer clear-cut advantages on biochemical and histological parameters over ARB alone, although it further improved the kidney NF-κB and gene expression profile.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22302208     DOI: 10.1093/ndt/gfr671

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  4 in total

1.  Tangeretin ameliorates renal failure via regulating oxidative stress, NF-κB-TNF-α/iNOS signalling and improves memory and cognitive deficits in 5/6 nephrectomized rats.

Authors:  Jing Wu; Yu-Mei Zhao; Zhi-Kuan Deng
Journal:  Inflammopharmacology       Date:  2017-09-04       Impact factor: 4.473

Review 2.  Unilateral ureteral obstruction: beyond obstruction.

Authors:  Alvaro C Ucero; Alberto Benito-Martin; Maria C Izquierdo; Maria D Sanchez-Niño; Ana B Sanz; Adrian M Ramos; Sergio Berzal; Marta Ruiz-Ortega; Jesus Egido; Alberto Ortiz
Journal:  Int Urol Nephrol       Date:  2013-09-27       Impact factor: 2.370

3.  Rutin ameliorates renal fibrosis and proteinuria in 5/6-nephrectomized rats by anti-oxidation and inhibiting activation of TGFβ1-smad signaling.

Authors:  Yu Han; Jin-Shan Lu; Yong Xu; Lei Zhang; Bao-Fa Hong
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

Review 4.  Fibrosis: a key feature of Fabry disease with potential therapeutic implications.

Authors:  Frank Weidemann; Maria D Sanchez-Niño; Juan Politei; João-Paulo Oliveira; Christoph Wanner; David G Warnock; Alberto Ortiz
Journal:  Orphanet J Rare Dis       Date:  2013-08-06       Impact factor: 4.123

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.